124 related articles for article (PubMed ID: 6678875)
21. Regional targeting of bisantrene by directed intravascular precipitation.
Kovach JS; Buck M; Tsukamoto T; Odegaard A; Lieber MM
Cancer Chemother Pharmacol; 1985; 15(3):192-5. PubMed ID: 4053264
[TBL] [Abstract][Full Text] [Related]
22. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene).
Wang BS; Lumanglas AL; Ruszala-Mallon VM; Durr FE
Cancer Res; 1984 Jun; 44(6):2363-7. PubMed ID: 6426780
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of bisantrene in non-small cell lung cancer.
Miller TP; Ahmann FR; Mackel C; Greenberg BR; Alberts DS
Invest New Drugs; 1985; 3(4):393-5. PubMed ID: 4086247
[TBL] [Abstract][Full Text] [Related]
24. Light, fluorescent, and electron microscopic analysis of cultured breast tumor cells (T-47D) treated with 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride.
Tseng MT; Safa AR
Cancer Res; 1983 Dec; 43(12 Pt 1):5910-4. PubMed ID: 6640539
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors.
Pratt CB; Sinkule JA; Etcubanas E; Douglass EC; Crom DB; Choi K; Avery L
Invest New Drugs; 1986; 4(2):149-53. PubMed ID: 3733375
[TBL] [Abstract][Full Text] [Related]
27. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.
Dorr RT; Peng YM; Alberts DS
Invest New Drugs; 1984; 2(4):351-7. PubMed ID: 6096286
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL).
Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S
Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237
[TBL] [Abstract][Full Text] [Related]
29. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
30. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
31. Bisantrene, an active new drug in the treatment of metastatic breast cancer.
Yap HY; Yap BS; Blumenschein GR; Barnes BC; Schell FC; Bodey GP
Cancer Res; 1983 Mar; 43(3):1402-4. PubMed ID: 6825109
[TBL] [Abstract][Full Text] [Related]
32. Bisantrene hydrochloride in gastric adenocarcinoma: a Southwest Oncology Group Study.
Panettiere FJ; Jones SE; Oishi N; Eyre HJ; O'Bryan RM; Andes WA; Taylor SA; Grozea PN
Med Pediatr Oncol; 1986; 14(2):78-80. PubMed ID: 3713640
[TBL] [Abstract][Full Text] [Related]
33. Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay.
Buck M; Kovach JS
Cancer Chemother Pharmacol; 1985; 15(1):40-3. PubMed ID: 4006048
[TBL] [Abstract][Full Text] [Related]
34. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
35. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
36. Phase II trial of bisantrene in advanced colorectal carcinoma.
Ahmed T; Kemeny NE; Michaelson RA; Harper HD
Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
[No Abstract] [Full Text] [Related]
37. Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.
Vogelzang NJ; Lanzotti VJ; Muntean B; Blough RR
Invest New Drugs; 1990 Aug; 8(3):313-5. PubMed ID: 2272771
[No Abstract] [Full Text] [Related]
38. Phase II trial of bisantrene in patients with metastatic melanoma.
Mackel C; Meyskens FL; Alberts DS
Cancer Treat Rep; 1986 Aug; 70(8):1037-8. PubMed ID: 3731151
[No Abstract] [Full Text] [Related]
39. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
Bowden GT; Roberts R; Alberts DS; Peng YM; Garcia D
Cancer Res; 1985 Oct; 45(10):4915-20. PubMed ID: 4027978
[TBL] [Abstract][Full Text] [Related]
40. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]